454 related articles for article (PubMed ID: 11729097)
1. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.
Abounader R; Lal B; Luddy C; Koe G; Davidson B; Rosen EM; Laterra J
FASEB J; 2002 Jan; 16(1):108-10. PubMed ID: 11729097
[TBL] [Abstract][Full Text] [Related]
2. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation.
Lal B; Xia S; Abounader R; Laterra J
Clin Cancer Res; 2005 Jun; 11(12):4479-86. PubMed ID: 15958633
[TBL] [Abstract][Full Text] [Related]
3. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J
J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431
[TBL] [Abstract][Full Text] [Related]
4. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4.
Brockmann MA; Papadimitriou A; Brandt M; Fillbrandt R; Westphal M; Lamszus K
Clin Cancer Res; 2003 Oct; 9(12):4578-85. PubMed ID: 14555533
[TBL] [Abstract][Full Text] [Related]
6. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
Martens T; Schmidt NO; Eckerich C; Fillbrandt R; Merchant M; Schwall R; Westphal M; Lamszus K
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6144-52. PubMed ID: 17062691
[TBL] [Abstract][Full Text] [Related]
7. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells.
Davies G; Watkins G; Mason MD; Jiang WG
Prostate; 2004 Sep; 60(4):317-24. PubMed ID: 15264243
[TBL] [Abstract][Full Text] [Related]
8. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
9. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo.
Laterra J; Nam M; Rosen E; Rao JS; Lamszus K; Goldberg ID; Johnston P
Lab Invest; 1997 Apr; 76(4):565-77. PubMed ID: 9111517
[TBL] [Abstract][Full Text] [Related]
10. Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4.
Heideman DA; van Beusechem VW; Bloemena E; Snijders PJ; Craanen ME; Offerhaus GJ; Derksen PW; de Bruin M; Witlox MA; Molenaar B; Meijer CJ; Gerritsen WR
J Gene Med; 2004 Mar; 6(3):317-27. PubMed ID: 15026993
[TBL] [Abstract][Full Text] [Related]
11. Met and hepatocyte growth factor/scatter factor expression in human gliomas.
Koochekpour S; Jeffers M; Rulong S; Taylor G; Klineberg E; Hudson EA; Resau JH; Vande Woude GF
Cancer Res; 1997 Dec; 57(23):5391-8. PubMed ID: 9393765
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.
Cao B; Su Y; Oskarsson M; Zhao P; Kort EJ; Fisher RJ; Wang LM; Vande Woude GF
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7443-8. PubMed ID: 11416216
[TBL] [Abstract][Full Text] [Related]
13. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways.
Bowers DC; Fan S; Walter KA; Abounader R; Williams JA; Rosen EM; Laterra J
Cancer Res; 2000 Aug; 60(15):4277-83. PubMed ID: 10945642
[TBL] [Abstract][Full Text] [Related]
14. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
[TBL] [Abstract][Full Text] [Related]
15. Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth.
Laterra J; Rosen E; Nam M; Ranganathan S; Fielding K; Johnston P
Biochem Biophys Res Commun; 1997 Jun; 235(3):743-7. PubMed ID: 9207232
[TBL] [Abstract][Full Text] [Related]
16. Sp1 regulates expression of MET, and ribozyme-induced down-regulation of MET in fibrosarcoma-derived human cells reduces or eliminates their tumorigenicity.
Liang H; O'Reilly S; Liu Y; Abounader R; Laterra J; Maher VM; McCormick JJ
Int J Oncol; 2004 May; 24(5):1057-67. PubMed ID: 15067326
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+).
Weimar IS; Miranda N; Muller EJ; Hekman A; Kerst JM; de Gast GC; Gerritsen WR
Exp Hematol; 1998 Aug; 26(9):885-94. PubMed ID: 9694510
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor (HGF) and receptor (c-met) in normal and malignant astrocytic cells.
Welch WC; Kornblith PL; Michalopoulos GK; Petersen BE; Beedle A; Gollin SM; Goldfarb RH
Anticancer Res; 1999; 19(3A):1635-40. PubMed ID: 10470094
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of VEGF, c-Met and HGF/SF in secondary pleural tumors.
Naim R; Tolnay E; Mueller KM; Kuhnen C
Int J Mol Med; 2004 Nov; 14(5):787-91. PubMed ID: 15492846
[TBL] [Abstract][Full Text] [Related]
20. Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET.
Jiang WG; Grimshaw D; Martin TA; Davies G; Parr C; Watkins G; Lane J; Abounader R; Laterra J; Mansel RE
Clin Cancer Res; 2003 Sep; 9(11):4274-81. PubMed ID: 14519655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]